<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gripp KW</submitter><funding>NIGMS NIH HHS</funding><pagination>2106-18</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4166655</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>158A(9)</volume><pubmed_abstract>Costello syndrome is caused by HRAS germline mutations affecting Gly(12) or Gly(13) in >90% of cases and these are associated with a relatively homogeneous phenotype. Rarer mutations in other HRAS codons were reported in patients with an attenuated or mild phenotype. Disease-associated HRAS missense mutations result in constitutive HRAS activation and increased RAF-MEK-ERK and PI3K-AKT signal flow. Here we report on a novel heterozygous HRAS germline alteration, c.266C>G (p.S89C), in a girl presenting with severe fetal hydrops and pleural effusion, followed by a more benign postnatal course. A sibling with the same mutation and fetal polyhydramnios showed a Dandy-Walker malformation; his postnatal course was complicated by severe feeding difficulties. Their apparently asymptomatic father i</pubmed_abstract><journal>American journal of medical genetics. Part A</journal><pubmed_title>A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.</pubmed_title><pmcid>PMC4166655</pmcid><funding_grant_id>8P20GM103464</funding_grant_id><funding_grant_id>P20 GM103446</funding_grant_id><funding_grant_id>P20 GM103464</funding_grant_id><pubmed_authors>Stabley DL</pubmed_authors><pubmed_authors>Rosenberger G</pubmed_authors><pubmed_authors>Sol-Church K</pubmed_authors><pubmed_authors>Gripp KW</pubmed_authors><pubmed_authors>Hopkins E</pubmed_authors><pubmed_authors>Meien S</pubmed_authors><pubmed_authors>Vinette K</pubmed_authors><pubmed_authors>Bifeld E</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.</name><description>Costello syndrome is caused by HRAS germline mutations affecting Gly(12) or Gly(13) in >90% of cases and these are associated with a relatively homogeneous phenotype. Rarer mutations in other HRAS codons were reported in patients with an attenuated or mild phenotype. Disease-associated HRAS missense mutations result in constitutive HRAS activation and increased RAF-MEK-ERK and PI3K-AKT signal flow. Here we report on a novel heterozygous HRAS germline alteration, c.266C>G (p.S89C), in a girl presenting with severe fetal hydrops and pleural effusion, followed by a more benign postnatal course. A sibling with the same mutation and fetal polyhydramnios showed a Dandy-Walker malformation; his postnatal course was complicated by severe feeding difficulties. Their apparently asymptomatic father i</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Sep</publication><modification>2026-04-29T16:56:32.648Z</modification><creation>2019-03-27T01:35:50Z</creation></dates><accession>S-EPMC4166655</accession><cross_references><pubmed>22821884</pubmed><doi>10.1002/ajmg.a.35449</doi></cross_references></HashMap>